NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
First Claim
Patent Images
1. A peptide dimer compound comprising two linked monomer subunits of Formula (I):
-
Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14
(Formula (I))or a pharmaceutically acceptable salt thereof,wherein;
Xaa1 is absent, Ac, or any amino acid;
Xaa2 is absent, Ac, or any amino acid;
Xaa3 is absent, Ac, or any amino acid;
Xaa4 is Pen or Cys;
Xaa5 is selected from the group consisting of;
N-Me-Arg, Arg, N-Me-Lys, Phe(4-guanidinoguanidino), Phe(4-carbomyl), Cit, Phe(4-NH2), N-Me-homoArg, homoArg, Tyr, Dap, Dab, Arg-Me-sym, Arg-Me-asym, Cav, and His;
Xaa6 is Ser, Ile, Gly, Thr or Ile;
Xaa7 is Asp, Asp(OMe) or N-Me-Asp;
Xaa8 is selected from the group consisting of;
Thr, Val, Ile, Leu, homoLeu, Gln, Ser, Asp, Pro, Gly, His, Ala, Phe, Lys, Arg, Asn, Glu, Tyr, Trp, Met, Nle, and N-methyl amino acids, including N-Me-Thr;
Xaa9 is selected from the group consisting of;
Gln, Ser, Asp, Pro, Gly, Ala, Phe, Glu, Ile, Val, N-butyl Ala, N-pental Ala, N-hexyl Ala, cyclobutyl Ala, cyclopentylAla, Leu, Nle, Cba, homoLeu, Cpa, Aoc, and N-Me-Leu;
Xaa10 is Pen;
Xaa11 is absent or selected from the group consisting of;
aromatic amino acids, substituted aromatic amino acids, and Tic;
Xaa12 is absent or selected from the group consisting of;
aromatic amino acids, substituted aromatic amino acids, Glu, D-Glu, homoGlu, Asp, D-Asp, D-homoGlu, Gla, beta-homoGlu, Tic, Aic, Gin, Cit, Glu(OMe), Asn, D-His, Tic, Phe(3-COOH), D-Arg, Bip, D-Trp, Phe, D-Phe, D-Val, D-Thr, D-Tyr, D-Lys, D-Ile, D-His, N-Me-Glu, N-Me-Asp, alpha-homoGlu, Biphenyl-Gly, Biphenyl-Ala, Homo-Phe, D-1-Nal, D-2-Nal, Thr, and Val, and corresponding D-amino acids and isosteres;
Xaa13 is absent or Pro or any amino acid; and
Xaa14 is selected from the group consisting of;
any amino acid with an amine side chain, Lys, D-Lys, N-Me-Lys, D-N-Me-Lys, Orn, Dab, Dap, HomoLys, D-Dap, D-Dab, D-Orn, Cys, HomoCys, Pen, D-HomoCys, D-Cys, D-Pen, Asp, Glu, D-Asp, D-Glu and HomoSer, HomoGlu, D-homoGlu, N-Me-Glu, N-Me-Asp, N-Me-D-Glu, and N-Me-D-Asp;
wherein one or both monomer subunits of the peptide dimer compound comprises a disulfide bond between Xaa4 and Xaa10.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to peptide dimer compounds and peptide monomer compounds that potently inhibit binding of α4β7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, possess high selectivity against α4β1 binding, and have high stability under gastrointestinal conditions.
15 Citations
28 Claims
-
1. A peptide dimer compound comprising two linked monomer subunits of Formula (I):
-
Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14
(Formula (I))or a pharmaceutically acceptable salt thereof, wherein; Xaa1 is absent, Ac, or any amino acid; Xaa2 is absent, Ac, or any amino acid; Xaa3 is absent, Ac, or any amino acid; Xaa4 is Pen or Cys; Xaa5 is selected from the group consisting of;
N-Me-Arg, Arg, N-Me-Lys, Phe(4-guanidinoguanidino), Phe(4-carbomyl), Cit, Phe(4-NH2), N-Me-homoArg, homoArg, Tyr, Dap, Dab, Arg-Me-sym, Arg-Me-asym, Cav, and His;Xaa6 is Ser, Ile, Gly, Thr or Ile; Xaa7 is Asp, Asp(OMe) or N-Me-Asp; Xaa8 is selected from the group consisting of;
Thr, Val, Ile, Leu, homoLeu, Gln, Ser, Asp, Pro, Gly, His, Ala, Phe, Lys, Arg, Asn, Glu, Tyr, Trp, Met, Nle, and N-methyl amino acids, including N-Me-Thr;Xaa9 is selected from the group consisting of;
Gln, Ser, Asp, Pro, Gly, Ala, Phe, Glu, Ile, Val, N-butyl Ala, N-pental Ala, N-hexyl Ala, cyclobutyl Ala, cyclopentylAla, Leu, Nle, Cba, homoLeu, Cpa, Aoc, and N-Me-Leu;Xaa10 is Pen; Xaa11 is absent or selected from the group consisting of;
aromatic amino acids, substituted aromatic amino acids, and Tic;Xaa12 is absent or selected from the group consisting of;
aromatic amino acids, substituted aromatic amino acids, Glu, D-Glu, homoGlu, Asp, D-Asp, D-homoGlu, Gla, beta-homoGlu, Tic, Aic, Gin, Cit, Glu(OMe), Asn, D-His, Tic, Phe(3-COOH), D-Arg, Bip, D-Trp, Phe, D-Phe, D-Val, D-Thr, D-Tyr, D-Lys, D-Ile, D-His, N-Me-Glu, N-Me-Asp, alpha-homoGlu, Biphenyl-Gly, Biphenyl-Ala, Homo-Phe, D-1-Nal, D-2-Nal, Thr, and Val, and corresponding D-amino acids and isosteres;Xaa13 is absent or Pro or any amino acid; and Xaa14 is selected from the group consisting of;
any amino acid with an amine side chain, Lys, D-Lys, N-Me-Lys, D-N-Me-Lys, Orn, Dab, Dap, HomoLys, D-Dap, D-Dab, D-Orn, Cys, HomoCys, Pen, D-HomoCys, D-Cys, D-Pen, Asp, Glu, D-Asp, D-Glu and HomoSer, HomoGlu, D-homoGlu, N-Me-Glu, N-Me-Asp, N-Me-D-Glu, and N-Me-D-Asp;wherein one or both monomer subunits of the peptide dimer compound comprises a disulfide bond between Xaa4 and Xaa10. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 16, 17, 23, 24, 25, 26, 27)
Xaa8 is selected from the group consisting of Leu, homoLeu, Nle and Val; Xaa9 is selected from the group consisting of Cba, homoLeu, and Cpa; Xaa11 is selected from the group consisting of Tic, Phe(2-carbomyl), Phe(3-carbomyl), Phe(4-COOH), Phe(4-OMe), and Phe(4-tBu); Xaa12 is selected from the group consisting of Aic, Gln, Cit, Glu(OMe), D-His, Tic, Phe(3-COOH), D-Arg, Bip, D-Trp, Phe, D-Phe, D-Val, D-Thr, D-1-Nal, D-2-Nal, Thr, Val;
orXaa13 is Pro.
-
-
6. The peptide dimer compound of claim 1, wherein Xaa5 is N-Me-Arg, Xaa6 is Ser, Xaa7 is Asp, Xaa8 is Thr, and/or Xaa9 is Leu.
-
7. The peptide dimer compound of claim 1, wherein Xaa1l is Tic, Phe(2-carbomyl), Phe(3-carbomyl), Phe(4-COOH), Phe(4-OMe), or Phe(4-tBu).
-
8. The peptide dimer compound of claim 1, wherein:
-
Xaa5 is N-Methyl-Arg; Xaa6 is Ser; Xaa7 is Asp; Xaa8 is Thr or Val; Xaa9 is Leu; Xaa11 is selected from the group consisting of;
Trp, Phe, 2-Nal, 1-Nal, Tyr, His, Phe(4-F), Phe(4-CF3), Phe(4-CH3), Phe(4-tBu), Bip, Phe(4-COOH), Gly, 3,3-DiPhenylGly, 3,3 diPhenyl Ala, Tic, β
-homoTrp, D-1-Nal, D-2-Nal, Phe(2,4-diCl), Phe(3,4-diCl), Phe(4-carbomyl), Phe(3-Carbomyl), Tyr(Me), and HomoPhe;Xaa12 is selected from the group consisting of;
any aromatic amino acid, Glu, D-Glu, and beta-homoGlu;Xaa13 is absent; and Xaa14 is selected from the group consisting of;
D-Lys, N-Me-Lys, and D-N-Me-Lys.
-
-
9. The peptide dimer compound of claim 8, wherein both subunits comprise one of the following sequences:
-
11. The peptide dimer compound of claim 9, where the subunits are linked via a DIG linker.
-
12. The peptide dimer compound of claim 9, wherein the peptide dimer compound has one of the following structures:
-
16. The peptide dimer compound of claim 1, further comprising acylation at one or more position selected from the group consisting of Xaa1-Xaa3 and Xaa11-Xaa14.
-
17. The peptide dimer compound of claim 1, wherein Xaa1 and Xaa2 are absent, and Xaa3 is Ac;
- and one or more of Xaa11, Xaa12 and Xaa13 is absent.
-
23. The peptide monomer compound of claim 1, wherein the peptide monomer compound comprises one of the following sequences or structures:
-
24. A compound of claim 1, wherein the compound is detectably labeled.
-
25. A pharmaceutical composition comprising a compound of claim 1.
-
26. The composition of claim 24, further comprising an enteric coating, wherein the enteric coating protects and releases the pharmaceutical composition within a subject'"'"'s lower gastrointestinal system
-
27. A method for treating a subject afflicted with a condition that is associated with a biological function of an α
- 4β
7 integrin, the method comprising administering to the human an effective amount of a compound of claim 1.
- 4β
-
10. (canceled)
-
13-15. -15. (canceled)
-
18. (canceled)
-
19. A peptide monomer compound of Formula (IV):
-
Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13-Xaa14
(Formula (IV))or a pharmaceutically acceptable salt thereof, wherein; Xaa1 is absent, Ac, or any amino acid; Xaa2 is absent, Ac, or any amino acid; Xaa3 is absent, Ac, or any amino acid; Xaa4 is Pen and Cys; Xaa5 is selected from the group consisting of;
N-Me-Arg, Arg, N-Me-Lys, Phe(4-guanidino), Phe(4-carbomylamino), Cit, Phe(4-NH2), N-Me-homoArg, homoArg, Tyr, Dap, Dab, Arg-Me-sym, Arg-Me-asym, Cav, and His;Xaa6 is Ser Gly, Thr, or Ile; Xaa7 is Asp, Asp(OMe), or N-Me-Asp; Xaa8 is selected from the group consisting of;
Thr, Val, Ile, Leu, homoLeu, Gln, Ser, Asp, Pro, Gly, His, Ala, Phe, Lys, Arg, Asn, Glu, Tyr, Trp, Met, Nle, and N-methyl amino acids, including N-Me-Thr;Xaa9 is selected from the group consisting of;
Gln, Ser, Asp, Pro, Gly, Ala, Phe, Glu, Ile, Val, N-butyl Ala, N-pental Ala, N-hexyl Ala, cyclobutyl Ala, cyclopentylAla, Leu, Nle, Cpa, Cba, homoLeu, Aoc, and N-Me-Leu;Xaa10 is Pen; Xaa11 is absent or selected from the group consisting of;
Trp, Phe, 2-Nal, 1-Nal, Tyr, His, Phe(4-F), Phe(4-CF3), Phe(4-CH3), Phe(4-tBu), Bip, Phe(4-COOH), Gly, 3,3-DiPhenylGly, 3,3-DiPhenyl Ala, Tic, b-homoTrp, D-1-Nal, D-2-Nal, Phe(2,4-diCl), Phe(3,4-diCl), Phe(4-carbomyl), Phe(3-Carbomyl), Phe(2-carbomyl), Tyr(Me), homoPhe, N-Me-Phe, N-Me-Tyr, Ser, Sar, Dihydro Trp, Ile, Leu, Arg, Thr, aromatic amino acids, substituted aromatic amino acids, and Tic;Xaa12 is absent or selected from the group consisting of;
aromatic amino acids, substituted aromatic amino acids, Glu, D-Glu, homoGlu, Asp, D-Asp, D-homoGlu, Gla, beta-homoGlu, Tic, Aic, Gln, Cit, Glu(OMe), Asn, D-His, Tic, Phe(3-COOH), D-Arg, Bip, D-Trp, Phe, D-Phe, D-Val, D-Thr, D-Tyr, D-Lys, D-Ile, D-His, N-Me-Glu, N-Me-Asp, alpha-homoGlu, Biphenyl-Gly, Biphenyl-Ala, Homo-Phe, D-1-Nal, D-2-Nal, Thr, and Val, and corresponding D-amino acids and isosteres;Xaa13 is absent or Pro or any amino acid; and Xaa14 is any amino acid, wherein the peptide monomer compound comprises a disulfide bond between Xaa4 and Xaa10. - View Dependent Claims (22)
-
-
20. A peptide monomer compound of Formula (V):
-
Xaa1-Xaa2-Xaa3-Xaa4-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10
(Formula (V))or a pharmaceutically acceptable salt thereof, wherein the peptide compound comprises a disulfide bond Xaa1 and Xaa7; wherein Xaa1-Xaa10 of Formula (V) corresponds to Xaa4-Xaa13 of Formula (IV), and wherein Xaa1 is Pen; Xaa2 is selected from the group consisting of Cit, Phe(4-carbomyl), and N-Me-HomoArg; Xaa3 is Ser Gly, Thr, or Ile; Xaa4 is Asp, D-Asp, Asp(OMe), or N-Me-Asp; Xaa5 is selected from the group consisting of Leu, HomoLeu, Nle and Val; Xaa6 is selected from the group consisting of;
Cba, HomoLeu, and Cpa;Xaa7 is Pen; Xaa8 is selected from the group consisting of Tic, Phe(2-carbomyl), Phe(3-carbomyl), Phe(4-COOH), Phe(4-OMe), and Phe(4-tBu); Xaa9 is selected from the group consisting of Aic, Gln, Cit, Glu(OMe), D-His, Tic, Phe(3-COOH), D-Arg, Bip, D-Trp, Phe, D-Phe, D-Val, D-Thr, D-1-Nal, D-2-Nal, Thr, Val; and Xaa10 is Pro.
-
-
21. (canceled)
-
28-41. -41. (canceled)
Specification